<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042285</url>
  </required_header>
  <id_info>
    <org_study_id>R2158</org_study_id>
    <nct_id>NCT04042285</nct_id>
  </id_info>
  <brief_title>Extracorporeal Shockwave Therapy for Diabetic Foot Wounds</brief_title>
  <official_title>Extracorporeal Shockwave Therapy for Diabetic Foot Wounds: A Cohort Study Comparing Extracorporeal Shockwave Therapy to Standard Treatment for Diabetic Foot Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hull University Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Hull</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hull University Teaching Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic wounds post digital amputation have poor healing in 30-45% of cases, resulting in&#xD;
      75% of patients undergoing a further amputation within the year, despite best wound&#xD;
      management.&#xD;
&#xD;
      Extracorporeal shockwave therapy is a promising safe and non invasive treatment that has been&#xD;
      shown to improve healing in chronic ulcers and burns by promoting healing and decreasing risk&#xD;
      of infection.&#xD;
&#xD;
      The study will recruit patients on a hospital ward who have undergone a toe amputation for a&#xD;
      infected non healing diabetic foot ulcer. Participants will be informed about the study,&#xD;
      given an patient information sheet and invited to give informed consent.&#xD;
&#xD;
      Consenting participants will undergo shockwave therapy three times in the seven days after&#xD;
      their operation, in addition to standard wound care.&#xD;
&#xD;
      Wound measurements, blood perfusion, tissue integrity, quality of life and pain scores will&#xD;
      be recorded at baseline, after the third treatment, 4 weeks, 8 weeks and 12 weeks after&#xD;
      recruitment to the study.&#xD;
&#xD;
      The study aims to recruit 25 patients.&#xD;
&#xD;
      The results will be compared to a matched retrospective cohort group who received standard&#xD;
      wound care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">May 20, 2022</completion_date>
  <primary_completion_date type="Actual">December 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound volume</measure>
    <time_frame>Baseline, up to 7 days, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>Change in wound volume between study visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score Questionnaire</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>Brief Pain Inventory and Visual Analogue Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>SF-12 and EQ-5Q-3L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rate</measure>
    <time_frame>Recorded at evey study contact</time_frame>
    <description>The number of wounds which develop an infection in the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation rate</measure>
    <time_frame>Recorded at every study contact</time_frame>
    <description>The number of amputations of treated sites in the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local perfusion rate</measure>
    <time_frame>Baseline, up to 7 days</time_frame>
    <description>blood flow perfusion rate of superficial tissues using Doppler flowmetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue integrity</measure>
    <time_frame>Baseline, up to 7 days</time_frame>
    <description>Tissue hydration determined by a vapometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Diabetic Foot</condition>
  <condition>Wound</condition>
  <arm_group>
    <arm_group_label>Extracorporeal shockwave therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second (17). Participants will receive 3 sessions of shockwave therapy in a 7-day period. In addition to standard wound care (dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard wound care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient with a diabetic foot wound who receive standard wound care, consisting of dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extracorporeal shockwave therapy</intervention_name>
    <description>Extracorporeal shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second. Participants will receive 3 sessions of shockwave therapy in a 7-day period.</description>
    <arm_group_label>Extracorporeal shockwave therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Wound Care</intervention_name>
    <description>dressing changes, negative pressure wound therapy, offloading footwear, debridement, glycaemic control and antibiotics as necessary</description>
    <arm_group_label>Standard wound care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus&#xD;
&#xD;
          -  Open surgical wound of the foot&#xD;
&#xD;
          -  ABPI &gt;0.8&#xD;
&#xD;
          -  Age greater than 18 years old&#xD;
&#xD;
          -  Able and willing to give written informed consent&#xD;
&#xD;
          -  Be able to adhere to protocol and attend all follow up appointments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Current malignancy&#xD;
&#xD;
          -  Allergy to materials used in the treatment&#xD;
&#xD;
          -  Palliative&#xD;
&#xD;
          -  Unable or unwilling to give consent&#xD;
&#xD;
          -  Anticoagulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George E Smith, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Vascular Surgery Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Foot Wound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

